GRAND RAPIDS, Mich.,
April 2, 2013 /PRNewswire/
-- Oncologix Tech Inc. (OTCBB: OCLG), a diversified medical
device and healthcare company acquiring businesses in medical
device cancer detection and prevention and healthcare services, has
purchased all of the outstanding common stock of Dotolo Research
Corporation. Dotolo is the leading global colon cleansing and bowel
preparation medical device manufacturer, with more than two decades
of product research, development and sales. Additional information
can be found in the Company's Form 8-K as filed with the SEC.
"Dotolo is delighted to merge its efforts with Oncologix," said
Wayne Erwin, CEO of Dotolo, who now
has been elected Chairman and CEO of Oncologix. "We now can develop
a stronger position in the medical device field, especially
with products that support the detection and prevention of
colorectal cancer. This strategic move will help us fund increased
manufacturing capacity, increase current inventory levels, expand
our sales and marketing team and acquire other medical device and
healthcare-related companies." Mr. Erwin noted that this
acquisition continues the strategic mission of OCLG to develop
medical devices that assist in the detection, treatment and
prevention of liver and colon cancers. The Company will continue
its joint venture with German partner IUT targeting colorectal
liver metastasis.
Dotolo Highlights:
History: Dotolo is a FDA Registered, Class II, medical
device manufacturer in the hydro-colonic irrigation and bowel
preparation market. It began operations in 1989 and is the
worldwide leader in hardware and disposable products sales in its
field. It currently has an active customer base of more than 900
customers both domestically and internationally.
Patents: Dotolo owns numerous patents, with its primary
patent on the Toxygen hardware, namely U.S. Patent #5,788,650,
"Colon Hydrotherapy Apparatus" - Ultra Violet Water Filtration
System. This patent is valid through 2018 and protects the product
design and unique characteristics of our proprietary product both
domestically and internationally.
Market: Dotolo designs, manufactures and distributes the
Toxygen hardware system with disposable speculums and tubing. The
Company has a valid registration as a FDA Class II medical device
and is licensed by Health Canada, a CE mark for Europe. Dotolo is also currently in compliance
with ISO 9001:2000 and ISO 13485:2003 regulations. Its products are
primary used for colon and bowel preparation prior to medical
procedures such as a colonoscopy or OB/GYN medical procedures and
for individuals seeking health and wellness prevention and good
colon health. There are currently more than 18 million
colonoscopy procedures performed world-wide each year and Dotolo's
mission is to continue to be the preferred choice of colon
cleansing and bowel preparation by both patients and medical
professionals.
Facilities: Dotolo operates from two locations: 5,200
square feet of manufacturing and administrative space in
Phoenix, AZ and 1,500 square feet
of administration space in Clearwater,
FL. OCLG's headquarters will remain in Grand Rapids, MI.
Company CEO Wayne Erwin, 54, has
three decades of leadership and management experience in medical
device sales and marketing, and business operations. He previously
served as the COO of Electronic Health Network, in Charleston, SC, COO of Crossroads Regional
Hospital in Alexandria, LA and as
Regional Sales Director at Centerpulse Orthopedics in Austin, TX Mr. Erwin was a Field
Artillery Captain in the 101st Airborne Division of the U.S. Army,
based at Ft. Campbell, KY, with
assignments in both Panama and
Honduras. He has a B.S. in Biology
from Louisiana College.
Michael A. Kramarz, 43, has been
the CFO of Oncologix since July 2004.
He holds both a Certified Management Accountant designation (CMA)
and a Certified Public Accountant designation (CPA). Mr. Kramarz
has a B.S. in accounting from Aquinas
College and a M.S. in taxation from Grand Valley State University.
Barry Griffith, 44, who has been
a director of Oncologix since December
2004, remains on the Oncologix Board. Mr. Griffith provides
20 years of early stage medical device company experience to
Oncologix. Mr. Griffith has been involved in the introduction
of novel medical devices in the orthopedic, vascular, neurological
and cancer markets for companies such as Mitek, Schneider, Novoste
and Medtronic. He is the founder and principal of The Bench, an
executive search firm in the medical device industry based in
Newport Beach, California.
This press release may contain forward-looking statements, made
in reliance upon Section 21D of the Exchange Act of 1934, which
involve known and unknown risks, uncertainties or other factors
that could cause actual results to differ materially from the
results, performance, or expectations implied by these
forward-looking statements. The Company's expectations, among other
things, are dependent upon economic conditions, continued demand
for its products, the availability of raw materials, retention of
its key management and operating personnel, its ability to operate
its subsidiary companies effectively, need for and availability of
more capital as well as other uncontrollable or unknown factors
which are more fully disclosed in the Company's 8-K on file with
the Securities and Exchange Commission.
About Oncologix Tech, Inc.:
Oncologix is a diversified
medical device and healthcare holding company. For its customers,
Oncologix provides FDA approved medical devices and state licensed
healthcare services. For its shareholders, Oncologix acquires
profitable operations that build, maintain and nourish shareholder
value. The Company's corporate mission is to be the best small cap
medical device and healthcare holding company in North America.
About Dotolo Research Corporation:
Dotolo has been a
worldwide leader in developing, manufacturing and distributing
hardware and disposable products in the colon cleaning and bowel
preparation market for more than 20 years. Its products are
primarily used for colon and bowel preparation prior to medical
procedures, such as a colonoscopy or OB/GYN medical procedures, and
for those seeking health and wellness prevention and good colon
health.
Contact Information
Contact:
Wayne Erwin,
CEO
wayne.erwin@oncologix.biz
318-769-1958
SOURCE Oncologix Tech Inc.